| Developers: | Moscow Institute of Physics and Technology (MIPT) |
| Date of the premiere of the system: | 2025/03/14 |
| Branches: | Pharmaceuticals, Medicine, Healthcare |
The main articles are:
2025: Development of an antitumor drug for the treatment of breast cancer begins
On the basis of MIPT, a project was launched to develop an antitumor drug for the treatment of breast cancer. It is expected that by 2026 the team of scientists will prepare several panels of compounds that will be validated both in vitro and in vivo. The university announced this on March 14, 2025.
Breast cancer is the most common type of oncology among women, according to statistics from the World Health Organization (WHO). Every year, doctors record more than 2 million new cases of this disease around the world.
The project for the development of a drug for the treatment of breast oncopathology is led by Philip Maksimov, an international expert in the field of molecular oncology, who worked at the MD Anderson Cancer Center (Houston, USA) before MIPT. According to him, the drug under development for the treatment of breast cancer will be in the form of a pill.
 | We are working to make the treatment as comfortable as possible for patients. The development of a tablet formulation is more preferable in our case than the creation of injections. The thing is that it is painless for patients, - explained Philip Maksimov. |  |
In the first stage of work, it is planned to create several connection panels based on various chemical structures and molecular mechanisms of action. These compounds will be tested on cell cultures and then tested on animals.
| | Selection of lead compounds will be based on their potential activity and ability to bind to specific receptors, which is critical for the development of targeted therapies. In our case, therapy for the treatment of hormone receptor-positive breast cancer. We plan to use selective estrogen receptor degraders that are able to destroy receptors and prevent tumor growth, as well as new modifications of existing molecules that can improve their effectiveness, "explained Philip Maksimov. | |
The industrial partner of the project is the company ChemRar, which has extensive experience in the development and commercialization of pharmaceuticals. Collaboration with ChemRar will provide the MIPT research team with access to state-of-the-art testing methods and the necessary infrastructure to conduct animal testing.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |